BSC Buys Target; Sulzer Medica Spins Off
Executive SummaryFor the last couple of years, one of the most closely-watched battles in the medical device industry was that between Target Therapeutics Inc., with 1996 sales of $47.5mm, and its much larger competitors, Boston Scientific Corp. and Johnson & Johnson in the struggle for the market for miniature catheters used in minimally-invasive applications, particularly interventional neurology.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.